Efficacy and patient tolerability of travoprost bak-free solution in patients with open-angle glaucoma and ocular hypertension

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 877-888

  Mirza, Sophia K ^a   Johnson, Sandra M ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Benzalkonium chloride; Glaucoma; Sofzia; Travatan Z

Indexed keywords

EID: 77956120238     PISSN: 11775467     EISSN: 11775483     Source Type: Book Series    
DOI: 10.2147/opth.s6292     Document Type: Review

References (102)

1. Quigly HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262-267
2. Bourne RRA. Worldwide glaucoma through the looking glass. Br J Ophthalmol. 2006;90(3):253-254
3. Mendrinos E, Shaarawy T. Glaucoma surgery: toward a new global vision. Expert Rev Ophthalmol. 2007;2:149-153
4. World Health Organization. Prevention of blindness and visual impairment. Available from: http://www.who.int/blindness/causes/priority/en/index7.html
5. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120: 1268-1279
6. Friedman DS, Wolfs RC, O'Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol. 2004;122:532-538
7. Friedman DS, Jampel HD, Monoz B, et al. The prevalence of openangle glaucoma among blacks and whites 73 years or older: the Salisbury Eye Evaluation Glaucoma Study. Arch Ophthalmol. 2006;124: 1525-1630
8. Lee PP, Walt JG, Doyle JJ, et al. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol. 2006;124:12-19
9. Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study. Arch Ophthalmol. 2002;120(6):701-713
10. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normaltension glaucoma and patients with therapeutically reduced intraocular pressure. Am J Ophthalmol. 1998;126:487-497
11. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study (CIGTS) comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108:1943-1953
12. van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005;112:1177-1185
13. Lim KS, Nau CB, O'Byrne MM, et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects: a crossover study. Ophthalmology. 2008;115(5):790-795
14. Konstas AGP, Kozobolis VP, Katsimpris I, et al. Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients. Ophthalmology. 2007;114(4):653-657
15. Ali FS, Akpek EK. Glaucoma and dry eye. Ophthalmology. 2009; 116(6):1232.
16. Shaumberg DA, Sullivan DA, Buring JE, et al. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136:318-326
17. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118:1264-1268
18. McCarty CA, Bansal AK, Livingston PM, et al. The epidemiology of dry eye in Melbourne, Australia. Ophthalmology. 1998;105:1114-1119
19. Schein OD, Hochberg MC, Munoz B, et al. Dry eye and dry mouth in the elderly. Arch Intern Med. 1999;159:1359-1363
20. Doughty MJ, Fonn D, Richeter D, et al. A patient questionnaire approach to estimating the prevalence of dry eye symptoms in patients presenting to optometric practices across Canada. Optom Vis Sci. 1997;74:624-631
21. Lin PY, Tsai SY, Cheng CY, et al. Prevalence of dry eye among an elderly Chinese population in Taiwan: the Shihpai Eye Study. Ophthalmology. 2003;110:1096-1101
22. Lee AJ, Lee J, Saw S-M, et al. Prevalence and risk factors associated with dry eye symptoms: a population based study in Indonesia. Br J Ophthalmol. 2002;86:1347-1351
23. Shimmura S, Shimazaki J, Tsubota K. Results of a population-based questionnaire on the symptoms and lifestyles associated with dry eye. Cornea. 1999;18:408-411
24. Schiffman RM, Walt JG, Jacobsen G, et al. Utility assessment among patients with dry eye disease. Ophthalmology. 2003;110:1412-1419
25. Clegg JP, Guest JF, Lehman A, Smith AF. The annual cost of dry eye syndrome in France, Germany, Italy, Spain, Sweden, and the UK. Ophthalmic Epidemiol. 2006;13:263-274
26. Perry HD. Dry eye disease: pathophysiology, classification, and diagnosis. Am J Manag Care. 2008;14 Suppl 3:S79-S87.
27. Schmier JK, Covert DW. Characteristics of respondents with glaucoma and dry eye in a national panel survery. Clin Ophthalmol. 2009;3:645-650
28. Rossi GC, Tinelli C, Pasinetti GM, et al. Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol. 2009;19(4):572-579
29. Nordmann JP, Auzanneau N, Ricard S, Berdeaux G. Vision-related quality of life and topical glaucoma treatment side-effects. Health Qual Life Outcomes. 2003;1:75.
30. Malvitte L, Montange T, Vejux A, et al. Measurement of inflammatory cytokines by multicytokine assay in tears of patients with glaucoma topically treated with chronic drugs. Br J Ophthalmol. 2007;91: 29-32
31. Schwartz GF, Tan J, Kotak S. Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs. J Ocul Pharmacol Ther. 2009;25(6):555-561
32. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350-355
33. Friedman DS, Hahn SR, Gelb L, et al. Doctor-patient communication, health-related beliefs, and adherence in glaucoma results from the Glaucoma Adherence and Persistency Study. Ophthalmology. 2008;115: 1320-1327
34. Feldman RM. Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension. J Ocul Pharmacol Ther. 2003;19:23-35
35. Rees G, Leong O, Crowston JC, Lamoureux EL. Intentional and unintentional nonadherence to ocular hypotensive treatment in patients with glaucoma. Ophthalmology. 2010;117(5):903-908
36. Schwartz GF. Compliance and persistency in glaucoma follow-up treatment. Current Opin Ophthalmol. 2005;16(2):114-121
37. Parrish RK, Palmberg P, Sheu WP; for XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135(5):688-703
38. Broadway DC, Chang LP. Trabeculectomy, risk factors for failing and the preoperative state of the conjunctiva. J Glaucoma. 2001;10: 237-249
39. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative-free glaucoma medication. Br J Ophthalmol. 2002;86:418-423
40. Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17:341-349
41. Rahman MQ, Tejwani D, Wilson JA, Butcher I, Ramaesh K. Microbial contamination of preservative free eye drops in multiple application containers. Br J Ophthalmol. 2006;90:139-141
42. Schein OD, Hibberd PL, Starch T, Baker AS, Kenyan KR. Microbial contamination of the in-use ocular medications. Arch Ophthalmol. 1992;110:82-85
43. Geyer O, Bottone EJ, Podos SM, Schumer RA, Asbell PA. Microbial contamination of medications used to treat glaucoma. Br J Ophthalmol. 1995;79:376-379
44. Whitson JT, Varner DL, Grove D, Netland PA. Glaucoma drugs and the ocular surface. Rev Ophthalmol. 2006;13(11):69-79
45. Burnstein NL, Klyce SD. Electrophysiologic and morphologic effects of ophthalmic preparations on rabbit cornea epithelium. Invest Ophthalmol Vis Sci. 1977;6:899-911
46. Gasset AR, Ishii Y, Kaufman HE, Miller T. Cytotoxicity of ophthalmic preservatives. Am J Ophthalmol. 1974;7(1):98-105
47. Berdy GJ, Abelson MB, Smith LM, George MA. Preservative-free artificial tear preparations. Assessment of corneal epithelial toxic effects. Arch Ophthalmol. 1992;110:528-532
48. Tripathi BJ, Tripathi RC, Killi SP. Cytotoxicity of ophthalmic preservatives on human corneal epithelium. Lens Eye Toxic Res. 1992;9(3-4): 361-375
49. Burstein NL. The effects of topical drugs and preservatives on the tears and corneal epithelium in dry eye. Trans Ophthalmol Soc U K. 1985;104:402-409
50. Shaw AJ, Balls M, Clothier RH, Bateman ND. Predicting ocular irritancy and recovery from injury using Madin-Darby canine kidney cells. Toxicol In Vitro. 1991;5:169-174
51. Champeau EJ, Edelahuser HF. Effect of ophthalmic preservatives on the ocular surface: conjunctival and corneal uptake and distribution of benzalkonium chloride and chlorhexidine digluconate. In: Holly FJ, editor. The Preocular Tear Film. Lubbock, TX: Dry Eye Institute, Inc; 1986.
52. Ichijima H, Petroll WM, Jester JV, Cavanagh HD. Confocal microscopic studies of living rabbit cornea treated with benzalkonium chloride. Cornea. 1992;11:221-225
53. Yee RW. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. Current Opin Ophthalmology. 2007;18:134-139
54. de Saint Jean M, Brignole F, Bringuier AF, Bauchet A, Felmann G, Bauduoin C. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci. 1999;40: 619-630
55. Williams DE, Nguyen KD, Shapourifar-Tehrani S, Kitada S, Lee DA. Effects of timolol, betaxolol, and levobunolol on human tenon's fibroblasts in tissue culture. Invest Ophthalmol Vis Sci. 1992;33: 2233-2241
56. Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs. Ophthalmology. 1999;106(3):556-563
57. Debbasch C, Brignole F, Pisella PJ, et al. Quaternary ammoniums and other preservatives' contribution in oxidative stress and apoptosis on Chang conjunctival cells. Invest Ophthalmol Vis Sci. 2001;42: 642-652
58. Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci. 2004;45:1360-1368
59. Costagliola C, Prete AD, Incorvaia C, et al. Ocular surface changes induced by topical application of latanoprost and timolol: a short-term study in glaucomatous patients with and without allergic conjunctivitis. Graefes Arch Clin Exp Ophthalmol. 2001;239:809-814
60. Liesegang TJ. Conjunctival changes associated with glaucoma therapy: implications for the external disease consultant and treatment of glaucoma. Cornea. 1998;17:574-583
61. Guenoun JM, Baudouin C, Rat P, et al. In vitro study of inflammatory potential and toxicity profile between latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci. 2005;46:2444-2450
62. Guenoun JM, Baudouin C, Rat P, et al. In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci. 2005;40:4594-4599
63. Skuta GL, Parrish RK II. Wound healing in glaucoma filtering surgery. Surv Ophthalmol. 1987;80:624-627
64. Hitchings RA, Grierson I. Clinico-pathologic correlation in eyes with failed fistulizing surgery. Trans Ophthalmol Soc U K. 1983;103:84-88
65. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication, II: the outcome of filtration surgery. Arch Ophthalmol. 1994;112:1446-1454
66. Kuppens EV, de Jong CA, Stolwijk TR, de Kreizer RJ, van Best JA. Effects of timolol with and without preservative on the basal tear turnover in glaucoma. Br J Ophthalmol. 1993;77:590-596
67. Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glauocoma. Acta Ophthalmol. 2008;86:716-726
68. Young TL, Higginbotham EJ, Zou X, Farber MD. Effects of topical glaucoma drugs on fistulized rabbit conjunctiva. Ophthalmology. 1990;97:1423-1427
69. Lavin MJ, Wormald RPL, Migdal CS, Hitchings RA. Influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol. 1990;108:1543-1548
70. Johnson DH, Yoshikawa K, Brubaker RF, Hodge DO. The effect of long-term medical therapy on the outcome of filtration surgery. Am J Ophthalmol. 1994;117:139-148
71. Baudouin C. Mechanisms of failure in glaucoma filtering surgery: a consequence of antiglaucomatous drugs? Int J Clin Pharmacol Res. 1996;16:29-41
72. Baudouin C. Side effects of antiglaucomatous drugs on the ocular surface. Curr Opin Ophthalmol. 1996;7:80-86
73. Tamilvanan S, Benita S. The potential of lipid emulsion for ocular delivery of lipophilic drugs. Eur J Pharm Biopharm. 2004;58: 357-368
74. Sila-On W, Vardhanabhuti N, Ongpipattanakul B, Kulvanich P. The influence of physicochemical properties of preservative compounds on their distribution into various phases of oil in water submicron emulsion. PDA J Pharm Sci Technol. 2006;60:172-181
75. Sznitowska M, Janicki S, Dabrowska EA, Gajewska M. Physicochemical screening of antimicrobial agents as potential preservatives for submicron emulsions. Eur J Pharm Sci. 2002;15:489-495
76. Liang H, Brignole-Baudouin F, Rabinovich-Guilatt L, et al. Reduction of quaternary ammonium-induced ocular surface toxicity by emulsions: an in vivo study in rabbits. Mol Vis. 2008;14:204-216
77. Kaur IP, Lal S, Rana C, Kakkar S, Singh H. Ocular preservatives: associated risks and newer options. Cutan Ocul Toxicol. 2009;28(3): 93-103
78. Kahook MY. Travoprost Z ophthalmic solution with sofZia: clinical safety and efficacy. Expert Rev Ophthalmol. 2007;2:363-368
79. Mundorf T, Williams R, Whitcup S, et al. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2003;19(1):37-44
80. Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 2002;11(2):119-126
81. Baudouin C, Hamard P, Liang H, et al. Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology. 2004;111(12): 2186-2192
82. Ishibashi T, Yokoi N, Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma. 2003;12:486-490
83. Baudouin C, de Lunardo C. Short term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br J Ophthalmol. 1998;82:39-42
84. Vass C, Hirn C, Sycha T, et al. Medical interventions for primary open angle glaucoma and ocular hypertension. Cochrane Database Syst Rev. 2007;(4):CD003167.
85. Hodge WB, Lachaine J, Steffensen I, et al. The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review. Br J Ophthalmol. 2008;92:7-12
86. Eyawo O, Nachega J, Lefebvre P, et al. Efficacy and safety of prostaglandin analogues in patients with predominately primary open-angle glaucoma or ocular hypertension: a meta-analysis. Clin Ophthalmol. 2009;3:447-456
87. Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J Glaucoma. 2008;17(8):667-673
88. Lewis RA, Katz GJ, Weiss MJ, et al. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma. 2007;16(1):98-103
89. Godfrey DA, Peplinski LS, Stewart JA, Stewart WC. A comfort comparison of travoprost BAK-free 0.004% versus lantanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2009;3:189-194
90. Baudouin C, Riancho L, Warnet JM, Brignole F. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci. 2007;48(9):4123-4128
91. Yee R, Norcom EG, Zhao XC. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system. Adv Ther. 2006;23:511-518
92. Nguyen DH, Beuerman RW, de Wever B, Rosdy M. Three-dimensional construct of the human corneal epithelium for in vitro toxicology. In: Salem H, Katz SA, editors. Alternatives Toxicological Methods. Boca Raton, Florida: CRC Press; 2003:147-159
93. Morgan RL, Sorenson SS, Castles TR. Prediction of ocular irritation only corneal pachymetry. Food Chem Toxicol. 1987;25:609-613
94. Khoh-Reiter S, Jessen BA. Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model. BMC Ophthalmol. 2009;9:5.
95. Whitson JT, Cavanagah HD, Lakshman N, Petroll WM. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Adv Ther. 2006;23:663-671
96. Green K, Jack MC, Cheeks L, et al. Detergent penetration into young and adult rabbit eyes: comparative pharmacokinetics. Cutan Ocul Toxicol. 1987;6:89-107
97. Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea. 2008;27:339-343
98. Curren RD, Harbell JW. In vitro alternatives for ocular irritation. Environ Health Perspect. 1998;106:485-492
99. Roggeband R, York M, Pericoi M, Braun W. Eye irritation responses in rabbit and man after single applications of equal volumes of undiluted model liquid detergent products. Food Chem Toxicol. 2000;38: 727-734
100. Netland PA, Landry T, Sullivan EK, et al; for Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:472-484
101. Gross RL, Peace JH, Smith SE, et al. Duration of IOP reduction with travoprost BAK-free solution. J Glaucoma. 2008;17:217-222
102. Henry JC, Peace JH, Stewart JA, Stewart WC. Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy. Clin Ophthalmol. 2008;2:613-621